You have read all your free articles, to continue reading subscribe to read the rest of this content.
Novo Nordisk increased operating profit in local currencies by 13 percent and by 10 percent in Danish kroner to DKK 34.5 billion in 2014. Sales growth of 8 percent in local currencies was driven by increased sales of Levemir® and Victoza®. Sales also increased by 6 percent in Danish kronAlready a…
Calquence, a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been conditionally approved in China for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This is the first approved indication for Calquence in ChiAlready a subscriber Login You have…
Medicon Valley Alliance is to welcome Novo Nordisk Scandinavia and General Manager & VP, Novo Nordisk Scandinavia, Niels Abel Bonde to the +300 member strong Danish-Swedish MVA-family. A strategic priority “We consider it a strategic priority to be a part of the Swedish and Medicon Valley baAlready a subscriber Login…
Modus Therapeutics has announced that sevuparin for the treatment of SCD was granted rare pediatric disease designation by the US Food & Drug Administration (FDA). “We are very pleased with the FDA’s decision to grant a rare pediatric disease designation to sevuparin for SCD. The potentiAlready a subscriber Login You have…
